[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408562":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":44,"responsibleParty":61,"collaborators":26,"id":65,"slug":26,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care","PLACEBO_COMPARATOR","Participants in this group will receive standard of care as well as a saline infusion during the study period.",[13],"Drug: Saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Sub-Dissociative Ketamine","EXPERIMENTAL","Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.",[19],"Drug: Ketamine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Saline","Saline infusion",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ketamine","Continuous ketamine infusion at a dose of 0.2 mg\u002Fkg\u002Fhr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.",[15],[32,35],{"name":33,"affiliation":5,"role":34},"Anna Rockich, Pharm D","STUDY_DIRECTOR",{"name":36,"affiliation":5,"role":37},"Samuel Tyagi, MD","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":26,"email":43},"Eric Johnson, PharmD","CONTACT","8593235722","eric.johnson@uky.edu",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University of Kentucky Medical Center","RECRUITING","Lexington","Kentucky","40536","United States",{"type":53,"coordinates":54},"Point",[55,56],-84.47772,37.98869,{"lat":56,"lon":55},[59],{"name":40,"role":41,"phone":60,"phoneExt":26,"email":43},"859-323-5722",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Sam Tyagi","Assistant Professor","100408562",false,"NCT04600089","Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI","2020Ketamine","Inclusion Criteria:\n\n* willing to give informed consent\n* scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair\n* requires naloxone continuous infusion for spinal prophylaxis\n\nExclusion Criteria:\n\n* allergy to ketamine, acetaminophen, or fentanyl\n* diagnosis of schizophrenia\n* history of hydrocephalus or central nervous system mass\n* incarcerated individuals\n* pregnant or lactating individuals","ALL","18 Years","90 Years",{"count":76,"type":77},30,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).",[83,84,85],"Descending Aortic Dissection","Postoperative Pain","Thoracoabdominal Aortic Aneurysm",[87,88,89,90],"naloxone","ketamine","aortic repair","spinal cord ischemia","2025-10-15",{"date":93,"type":94},"2025-10-20","ACTUAL",{"date":96,"type":94},"2020-12-08",{"date":98,"type":77},"2027-08",{"name":63,"class":6},1]